Trial Information
A Study of DTC in Patients With AIDS and AIDS Related Complex
Inclusion Criteria
Inclusion Criteria
Concurrent Medication:
Allowed:
- Zidovudine (AZT).
Exclusion Criteria
Co-existing Condition:
Patients with the following are excluded:
- Active opportunistic infection or progressive Kaposi's sarcoma (KS).
- Dementia.
- Lymphoma.
Concurrent Medication:
Excluded within 3 weeks of study entry:
- Other experimental AIDS therapy.
Patients with the following are excluded:
- Active opportunistic infection or progressive Kaposi's sarcoma (KS).
Patients must be either HIV seropositive or have AIDS or AIDS related complex (ARC) and
have life expectancy of at least 6 months.
Type of Study:
Interventional
Study Design:
Primary Purpose: Treatment
Authority:
United States: Food and Drug Administration
Study ID:
010A
NCT ID:
NCT00002069
Start Date:
Completion Date:
Related Keywords:
- HIV Infections
- Ditiocarb
- Acquired Immunodeficiency Syndrome
- AIDS-Related Complex
- Acquired Immunodeficiency Syndrome
- HIV Infections
- AIDS-Related Complex
Name | Location |
San Francisco AIDS Clinic / San Francisco Gen Hosp |
San Francisco, California 941102859 |
Duke Univ Med Ctr |
Durham, North Carolina 27710 |
USC School of Medicine / Norris Cancer Hosp |
Los Angeles, California 90033 |
SUNY / Health Sciences Ctr at Brooklyn |
Brooklyn, New York 112032098 |
Univ of Arizona / Arizona Cancer Ctr |
Tucson, Arizona 85724 |
Portion Med Group |
Sherman Oaks, California 91403 |
Florida Keys Memorial Hosp |
Key West, Florida 33040 |
Dr Gary Brewton |
Houston, Texas 77027 |